The two terms get used interchangeably in job adverts, service specifications and ICB documents, and they describe different things. The difference decides what a service is measured on, which is why it is worth being precise about.
This piece sets out what each term covers, where they overlap, and what changes in a practice when the emphasis moves from one to the other.
The short answer
Medicines management is about the system: the processes, controls and cost of getting the right medicine to the right patient safely and efficiently. Medicines optimisation is about the outcome for the individual patient: whether the medicines they are on are actually doing what they were started to do, and what the patient thinks about taking them.
Medicines management asks whether the process worked. Medicines optimisation asks whether the patient is better off.
What medicines management covers
Medicines management is the older term and the wider operational one. In a GP practice it covers:
- Repeat prescribing systems and reauthorisation controls
- Formulary adherence and generic switching
- Prescribing budget management and cost-per-patient monitoring
- Safety alerts and drug recalls, and the process for actioning them
- Prescribing audits against local and national guidance
- Supply and shortage handling
- Interface work with community pharmacy and secondary care
The measures are process and cost measures. Items per patient, spend against budget, formulary compliance rate, percentage of alerts actioned within the window, backlog of unauthorised repeats.
What medicines optimisation covers
Medicines optimisation is a person-centred approach to safe and effective medicines use, aimed at getting the best possible outcomes for the patient from the medicines they take. It came into wide NHS use following Royal Pharmaceutical Society guidance in 2013 and the NICE guideline on medicines optimisation published in 2015.
It rests on four widely used guiding principles: understand the patient’s experience of their medicines, make evidence-based choices, make medicines use as safe as possible, and build the approach into routine practice rather than treating it as an occasional exercise.
In a practice it shows up as:
- Structured medication reviews with the patient’s own view recorded
- Deprescribing where a medicine is no longer doing the job it was started for
- Adherence work, including why a patient is not taking something
- Polypharmacy review in frailty and multi-morbidity
- Shared decision-making about trade-offs between conditions
- Outcome tracking rather than activity counting
The measures are patient measures. Medicines stopped, treatment burden reduced, adherence improved, admissions avoided, targets reached in long-term conditions.
Where they overlap
A great deal of daily work belongs to both. High-risk drug monitoring is a control system and a patient-safety outcome. A structured medication review is a scheduled process and a patient conversation. Repeat prescribing is an efficiency question and, when a patient has been on something for nine years without anyone asking why, an optimisation question.
The useful distinction is not which tasks belong where. It is which question the service is being held to.
Why the difference matters in practice
Consider two practices working the same patient list.
The first runs strong medicines management. Repeats are authorised on time, the formulary is followed, the prescribing budget is on track and safety alerts are actioned within a week. Every process measure is green.
The second runs the same processes, and also reviews its frailty cohort with the patients present, stops what is no longer earning its place, and records what each patient wants from their medicines.
Both practices are managing medicines well. Only the second can say whether the patients are better off, and only the second will find the 82-year-old on eleven medicines who has quietly stopped taking four of them.
This is why service specifications increasingly ask for optimisation language and outcome reporting. It is also why an SMR programme that counts reviews without recording the patient’s own view audits poorly: the count is a management measure standing in for an optimisation one.
What to look for in a service specification
Read what the reporting asks for, because that is what the service will actually deliver.
- Activity counts only (reviews completed, queries handled, items processed) describe a medicines management service, whatever the title says.
- Outcome measures (medicines stopped, treatment burden reduced, monitoring brought back into date, long-term condition targets reached) describe an optimisation service.
- Both is the honest answer for most primary care work, and the specification should say which measures carry weight when the two pull against each other.
Frequently asked questions
Is medicines optimisation just a new name for medicines management?
They describe different things. Medicines management covers the systems, controls and cost of getting medicines to patients safely and efficiently. Medicines optimisation covers whether the individual patient is getting the best possible outcome from the medicines they take, including their own view of them.
Which one does a clinical pharmacist do?
Both, and the balance is set by the service specification. Repeat authorisation, formulary work, alerts and prescribing audits sit on the management side; structured medication reviews, deprescribing, adherence work and polypharmacy review in frailty sit on the optimisation side.
What are the four principles of medicines optimisation?
Understand the patient’s experience of their medicines, make evidence-based choices, make medicines use as safe as possible, and make the approach part of routine practice. They came into wide NHS use through Royal Pharmaceutical Society guidance in 2013 and are reflected in the NICE medicines optimisation guideline published in 2015.
How do we tell which one our current service is delivering?
Look at the reporting. Activity counts such as reviews completed and queries handled describe a medicines management service. Outcome measures such as medicines stopped, monitoring brought back into date and long-term condition targets reached describe an optimisation service.
Does optimisation cost more than management?
Optimisation work is more clinical time per patient, because the review is longer and the patient is in the conversation. The return shows up in medicines stopped, treatment burden reduced and avoided admissions, so the comparison worth running is cost per outcome across a year against cost per processed item.
Where to start
Virtual Pharmacist delivers both sides as a managed clinical service. Our medicines optimisation and clinical medication review pages cover the outcome-facing work, and the structured medication review guide sets out what good documentation looks like.
